The DOI matches its Crossref record; 225 of the 227 references it cites were found in a registry or an index, and 1 are not checked yet.
Tumor targeting via EPR: Strategies to enhance patient responses
Open accessAbstract
The tumor accumulation of nanomedicines relies on the enhanced permeability and retention (EPR) effect. In the last 5-10 years, it has been increasingly recognized that there is a large inter- and intra-individual heterogeneity in EPR-mediated tumor targeting, explaining the heterogeneous outcomes of clinical trials in which nanomedicine formulations have been evaluated. To address this heterogeneity, as in other areas of oncology drug development, we have to move away from a one-size-fits-all tumor targeting approach, towards methods that can be employed to individualize and improve nanomedicine treatments. To this end, efforts have to be invested in better understanding the nature, the complexity and the heterogeneity of the EPR effect, and in establishing systems and strategies to enhance, combine, bypass and image EPR-based tumor targeting. In the present manuscript, we summarize key studies in which these strategies are explored, and we discuss how these approaches can be employed to enhance patient responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“They showed around 97% of the NPs are delivered to tumors by endothelial cells through an active process of transcytosis instead of passive transport.”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [161]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“A recent study by Chan W.C.W et al. demonstrated that inter-endothelial gaps in tumors may not be responsible for the transport of nanodrugs into solid tumors [161].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [161]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Contrary to the EPR mechanism, the frequency of the gaps on the endothelial lining in tumors is too low to account for the NP accumulation in the tumor site, which was observed by TEM analysis [161].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [161]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several studies have demonstrated that only 0.1 to 0.2% of the injected dose is efficient against tumor cells and exhibits significant anticancer effects [20,123,161].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [161]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, defining the dominant mechanism of the entry of NPs into tumors may help engineer effective delivery carriers to enhance cancer therapy [161].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [161]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“This study’s outcome is a challenge for the long-established EPR mechanism of drug delivery to solid tumors.”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [161]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W. J., Jones, L. A., Holt, J. A., Wong, S., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. A., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,817
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
Photodynamic therapy of cancer: An update
Agostinis, P., Berg, K., Cengel, K. A., Foster, T. H., Girotti, A. W., Gollnick, S. O., Hahn, S. M., Hamblin, M. R., Juzeniene, A., Kessel, D., et al. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20114 · Cited by 5,145
What Is the Evidence That Tumors Are Angiogenesis Dependent?
Folkman, J. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.1.4 · Cited by 4,509
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Research works printed but not linked: 1
- Frei, 1991, Clinical studies of combination chemotherapy for cancer, Synerg. Antagon. Chemother., 1, 103
Cited by
Sorted by citations
Targeted drug delivery strategies for precision medicines
Manzari, M. T., Shamay, Y., Kiguchi, H., Rosen, N., Scaltriti, M., & Heller, D. A. (2021) · Nature Reviews Materials · doi:10.1038/s41578-020-00269-6 · Cited by 1,183
Cancer nanomedicine for combination cancer immunotherapy
Nam, J., Son, S., Park, K. S., Zou, W., Shea, L. D., & Moon, J. J. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0108-1 · Cited by 955
Nanomedicine in cancer therapy
Fan, D., Cao, Y., Cao, M., Wang, Y., Cao, Y., & Gong, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01536-y · Cited by 986
Enhancing cancer immunotherapy with nanomedicine
Irvine, D. J., & Dane, E. L. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-019-0269-6 · Cited by 908
Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance
Wu, W. E., Klockow, J., Zhang, M., Lafortune, F., Chang, E., Jin, L., Wu, Y., & Daldrup-Link, H. E. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105780 · Cited by 877
Fang, J., Islam, W., & Maeda, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.005 · Cited by 757
Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment
Subhan, M. A., Yalamarty, S. S. K., Filipczak, N., Parveen, F., & Torchilin, V. P. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060571 · Cited by 623
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 641
Foulkes, R., Man, E., Thind, J., Yeung, S., Joy, A., & Hoskins, C. (2020) · Biomaterials Science · doi:10.1039/d0bm00558d · Cited by 596
Composition design and medical application of liposomes
Li, M., Du, C., Guo, N., Teng, Y., Meng, X., Sun, H., Li, S., Yu, P., & Galons, H. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.007 · Cited by 572
Nanotechnology in cancer diagnosis: progress, challenges and opportunities
Zhang, Y., Li, M., Gao, X., Chen, Y., & Liu, T. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0833-3 · Cited by 510
The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors
Izci, M., Maksoudian, C., Manshian, B. B., & Soenen, S. J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00779 · Cited by 506
The tumor EPR effect for cancer drug delivery: Current status, limitations, and alternatives
Sun, R., Xiang, J., Zhou, Q., Piao, Y., Tang, J., Shao, S., Zhou, Z., Bae, Y. H., & Shen, Y. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114614 · Cited by 474
El‐Sawy, H. S., Al-Abd, A. M., Ahmed, T. A., El‐Say, K. M., & Torchilin, V. P. (2018) · ACS Nano · doi:10.1021/acsnano.8b06104 · Cited by 436
Magnetic nanoparticles in biomedical applications: A review
Materón, E. M., Miyazaki, C. M., Carr, O., Joshi, N., Picciani, P. H. S., Dalmaschio, C. J., Davis, F., & Shimizu, F. M. (2021) · Applied Surface Science Advances · doi:10.1016/j.apsadv.2021.100163 · Cited by 456
Enzyme responsive drug delivery systems in cancer treatment
Shahriari, M., Zahiri, M., Abnous, K., Taghdisi, S. M., Ramezani, M., & Alibolandi, M. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.07.004 · Cited by 421
Phototherapy in cancer treatment: strategies and challenges
Cai, Y., Chai, T., Nguyen, W., Liu, J., Xiao, E., Ran, X., Ran, Y., Du, D., Chen, W., & Chen, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02140-y · Cited by 453
Advances in nanomaterial-based targeted drug delivery systems
Cheng, X., Xie, Q., & Sun, Y. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1177151 · Cited by 428
Fundamentals and developments in fluorescence-guided cancer surgery
Mieog, J. S. D., Achterberg, F. B., Zlitni, A., Hutteman, M., Burggraaf, J., Swijnenburg, R., Gioux, S., & Vahrmeijer, A. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00548-3 · Cited by 415
Park, J., Choi, Y., Chang, H., Um, W., Ryu, J. H., & Kwon, I. C. (2019) · Theranostics · doi:10.7150/thno.37198 · Cited by 397
Nanoemulsions for drug delivery
Wilson, R. J., Li, Y., Yang, G., & Zhao, C. (2021) · Particuology · doi:10.1016/j.partic.2021.05.009 · Cited by 410
Nanocarrier-based drug combination therapy for glioblastoma
Zhao, M., van Straten, D., Broekman, M. L. D., Véronique Préat, A., & Schiffelers, R. M. (2020) · Theranostics · doi:10.7150/thno.38147 · Cited by 385
Photoluminescent Nanoparticles for Chemical and Biological Analysis and Imaging
Algar, W. R., Massey, M., Rees, K., Higgins, R., Krause, K. D., Darwish, G. H., Peveler, W. J., Xiao, Z., Tsai, H.-Y., Gupta, R., et al. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01176 · Cited by 365
Current approaches of nanomedicines in the market and various stage of clinical translation
Shan, X., Gong, X., Li, J., Wen, J., Li, Y., & Zhang, Z. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.025 · Cited by 354
Strategies to improve the EPR effect: A mechanistic perspective and clinical translation
Ikeda-Imafuku, M., Wang, L. L.-W., Rodrigues, D., Shaha, S., Zhao, Z., & Mitragotri, S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.043 · Cited by 330
Chen, S., Zhong, Y., Fan, W., Xiang, J., Wang, G., Zhou, Q., Wang, J., Geng, Y., Sun, R., Zhang, Z., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00701-4 · Cited by 327
Xu, T., Ma, Y., Yuan, Q., Hu, H., Hu, X., Qian, Z., Rolle, J. K., Gu, Y., & Li, S. (2020) · ACS Nano · doi:10.1021/acsnano.9b09426 · Cited by 317
Lammers, T. (2024) · Advanced Materials · doi:10.1002/adma.202312169 · Cited by 311
Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets
Kopecka, J., Trouillas, P., Gašparović, A. Č., Gazzano, E., Assaraf, Y. G., & Riganti, C. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100670 · Cited by 296
Zi, Y., Yang, K., He, J., Wu, Z., Liu, J., & Zhang, W. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114449 · Cited by 268
Nanoparticle–hydrogel superstructures for biomedical applications
Jiang, Y., Krishnan, N., Heo, J., Fang, R. H., & Zhang, L. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.05.041 · Cited by 277
Harnessing Endogenous Stimuli for Responsive Materials in Theranostics
Cook, A. B., & Decuzzi, P. (2021) · ACS Nano · doi:10.1021/acsnano.0c09115 · Cited by 273
Taiariol, L., Chaix, C., Farre, C., & Moreau, E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00484 · Cited by 271
Pande, S. (2023) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2023.2247036 · Cited by 265
The mechanisms of nanoparticle delivery to solid tumours
Nguyen, L. N. M., Ngo, W., Lin, Z. P., Sindhwani, S., MacMillan, P., Mladjenovic, S. M., & Chan, W. C. W. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00154-9 · Cited by 288
Metallodrugs in cancer nanomedicine
Peña, Q., Wang, A., Zaremba, O., Shi, Y., Scheeren, H. W., Metselaar, J. M., Kiessling, F., Pallares, R. M., Wuttke, S., & Lammers, T. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00468a · Cited by 259
Self-citationFrontiers in the treatment of glioblastoma: Past, present and emerging
Janjua, T. I., Rewatkar, P. V., Ahmed-Cox, A., Saeed, I., Mansfeld, F. M., Kulshreshtha, R., Kumeria, T., Ziegler, D. S., Kavallaris, M., Mazzieri, R., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.012 · Cited by 265
Nanomedicine: How nanomaterials are transforming drug delivery, bio-imaging, and diagnosis
Kurul, F., Turkmen, H., Çetin, A. E., & Topkaya, S. N. (2025) · Next Nanotechnology · doi:10.1016/j.nxnano.2024.100129 · Cited by 280
Bajracharya, R., Song, J. G., Patil, B. R., Lee, S. H., Noh, H.-M., Kim, D.-H., Kim, G.-L., Seo, S.-H., Park, J., Jeong, S. H., et al. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2089296 · Cited by 265
Thermal immuno-nanomedicine in cancer
Yang, Z., Gao, D., Zhao, J., Yang, G., Guo, M., Wang, Y., Ren, X., Kim, J. S., Jin, L., Tian, Z., et al. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00717-y · Cited by 255
Ejigah, V., Owoseni, O., Backer, P. B., Ogundipe, O. D., Fisusi, F. A., & Adesina, S. K. (2022) · Polymers · doi:10.3390/polym14132601 · Cited by 251
Nanomedicine-based commercial formulations: current developments and future prospects
Thapa, R. K., & Kim, J. O. (2022) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-022-00607-6 · Cited by 251
Ligand density on nanoparticles: A parameter with critical impact on nanomedicine
Alkilany, A. M., Zhu, L., Weller‡, H., Mews, A., Parak, W. J., Barz, M., & Feliu, N. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.05.010 · Cited by 238
Hyperthermia and smart drug delivery systems for solid tumor therapy
Seynhaeve, A. L. B., Amin, M., Haemmerich, D., van Rhoon, G. C., & ten Hagen, T. L. M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.02.004 · Cited by 239
Enhancement of EPR Effect for Passive Tumor Targeting: Current Status and Future Perspectives
Vagena, I.-A., Malapani, C., Gatou, Μ.-A., Lаgopati, N., & Pavlatou, E. A. (2025) · Applied Sciences · doi:10.3390/app15063189 · Cited by 252
Zhou, Q., Dong, C., Fan, W., Jiang, H., Xiang, J., Qiu, N., Piao, Y., Xie, T., Luo, Y., Li, Z., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119902 · Cited by 217
Albarqi, H. A., Wong, L., Schumann, C., Sabei, F. Y., Korzun, T., Li, X., Hansen, M. N., Dhagat, P., Moses, A. S., Taratula, O. R., et al. (2019) · ACS Nano · doi:10.1021/acsnano.8b06542 · Cited by 220
Advanced Nanotechnology Leading the Way to Multimodal Imaging‐Guided Precision Surgical Therapy
Wang, C., Fan, W., Zhang, Z., Wen, Y., Xiong, L., & Chen, X. S. (2019) · Advanced Materials · doi:10.1002/adma.201904329 · Cited by 216
Nanomaterial surface modification toolkit: Principles, components, recipes, and applications
Kaymaz, S. V., Malekzad, H., Sarıgül, H., Soylukan, C., Akyüz, L., & Yüce, M. (2023) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2023.103035 · Cited by 217
Ferroptosis-driven nanotherapeutics for cancer treatment
Shan, X., Li, S., Sun, B., Chen, Q., Sun, J., He, Z., & Luo, C. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.008 · Cited by 209
Leo, V. D., Milano, F., Agostiano, A., & Catucci, L. (2021) · Polymers · doi:10.3390/polym13071027 · Cited by 209
Metallic nanoparticles as drug delivery system for the treatment of cancer
Desai, N., Momin, M. M., Khan, T. A., Gharat, S., Ningthoujam, R. S., & Omri, A. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1912008 · Cited by 204
Gu, W., Meng, F., Haag, R., & Zhong, Z. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.10.003 · Cited by 198
Panagi, M., Voutouri, C., Mpekris, F., Papageorgis, P., Martin, M. R., Martin, J. D., Demetriou, P., Pierides, C., Polydorou, C., Stylianou, A., et al. (2020) · Theranostics · doi:10.7150/thno.36936 · Cited by 195
Cellular senescence in cancer: from mechanisms to detection
Ou, H., Hoffmann, R. J., González‐López, C., Doherty, G. J., Korkola, J. E., & Muñoz‐Espín, D. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12807 · Cited by 208
Cell primitive-based biomimetic functional materials for enhanced cancer therapy
Luo, G., Chen, W., Zeng, X., & Zhang, X. (2020) · Chemical Society Reviews · doi:10.1039/d0cs00152j · Cited by 194
Tumor Abnormality-Oriented Nanomedicine Design
Zhou, Q., Xiang, J., Qiu, N., Wang, Y., Piao, Y., Shao, S., Tang, J., Zhou, Z., & Shen, Y. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00062 · Cited by 203
Mirzaei, S., Gholami, M. H., Zabolian, A., Saleki, H., Farahani, M. V., Hamzehlou, S., Far, F. B., Sharifzadeh, S. O., Samarghandian, S., Khan, H. Z., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105759 · Cited by 191
EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles
Santos, E. D. S., Nogueira, K. A. B., Crisóstomo, L. C. C. F., Martins, J. R. P., Reis, A. V. F., Neto, J. D. B. V., da Silva, I. J., Pessoa, C., Petrilli, R., & Eloy, J. O. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.120082 · Cited by 194
Bioengineered nanogels for cancer immunotherapy
Ma, X., Li, S., Liu, Y., Zhang, T., Xue, P., Kang, Y., Sun, Z., & Xu, Z. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00247g · Cited by 186
Organelle-level precision with next-generation targeting technologies
Saminathan, A., Zajac, M. A., Anees, P., & Krishnan, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00396-8 · Cited by 194
Recent Advances in Metal‐Phenolic Networks for Cancer Theranostics
Zhang, Z., Xie, L., Ju, Y., & Dai, Y. (2021) · Small · doi:10.1002/smll.202100314 · Cited by 168
Targeted modulation of immune cells and tissues using engineered biomaterials
Yousefpour, P., Ni, K., & Irvine, D. J. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-022-00016-2 · Cited by 170
Gold Nanoparticles in Cancer Theranostics
Gao, Q., Zhang, J., Gao, J., Zhang, Z., Zhu, H., & Wang, D. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.647905 · Cited by 172
Pu, Y., Yin, H., Dong, C., Xiang, H., Wu, W., Zhou, B., Du, D., Chen, Y., & Xu, H. (2021) · Advanced Materials · doi:10.1002/adma.202104641 · Cited by 165
Man, F., Gawne, P. J., & de Rosales, R. T. M. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.05.012 · Cited by 163
Liu, X., Jiang, J., & Meng, H. (2019) · Theranostics · doi:10.7150/thno.38587 · Cited by 164
Recent Advances in Stimulus‐Responsive Nanocarriers for Gene Therapy
Cheng, Y., Li, L., Hu, P., Yang, Y., Wei, W., Deng, X., Wang, L., Tay, F. R., & Ma, J. (2021) · Advanced Science · doi:10.1002/advs.202100540 · Cited by 163
Lim, S., Park, J., Shim, M. K., Um, W., Yoon, H. Y., Ryu, J. H., Lim, D., & Kim, K. (2019) · Theranostics · doi:10.7150/thno.38425 · Cited by 162
Near-infrared fluorescence imaging in immunotherapy
Ji, Y., Jones, C., Baek, Y., Park, G. K., Kashiwagi, S., & Choi, H. S. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.012 · Cited by 161
Biological and Medical Applications of Calcium Phosphate Nanoparticles
Sokolova, V., & Epple, M. (2021) · Chemistry - A European Journal · doi:10.1002/chem.202005257 · Cited by 162
Nano–Bio Interactions in Cancer: From Therapeutics Delivery to Early Detection
Liu, Y., Wang, J., Xiong, Q., Hornburg, D., Tao, W., & Farokhzad, O. C. (2020) · Accounts of Chemical Research · doi:10.1021/acs.accounts.0c00413 · Cited by 153
Chen, Q., Ma, X., Xie, L., Chen, W., Xu, Z., Song, E., Zhu, X., & Song, Y. (2021) · Nanoscale · doi:10.1039/d0nr08757b · Cited by 150
Carbon Dots: An Innovative Tool for Drug Delivery in Brain Tumors
Calabrese, G., Luca, G. D., Nocito, G., Rizzo, M. G., Lombardo, S. P., Chisari, G., Forte, S., Sciuto, E. L., & Sabrina Conoci, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111783 · Cited by 150
Challenges and pitfalls in the development of liposomal delivery systems for cancer therapy
Moosavian, S. A., Bianconi, V., Pirro, M., & Sahebkar, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.025 · Cited by 149
Luo, L., Qi, Y., Zhong, H., Jiang, S., Zhang, H., Cai, H., Wu, Y., Gu, Z., Gong, Q., & Luo, K. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.003 · Cited by 143
Abello, J., Nguyen, T. D. T., Marasini, R., Aryal, S., & Weiss, M. L. (2019) · Theranostics · doi:10.7150/thno.30030 · Cited by 142
Theranostic application of nanoemulsions in chemotherapy
Gorain, B., Choudhury, H., Nair, A. B., Dubey, S. K., & Kesharwani, P. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.04.013 · Cited by 139
Yafout, M., Ousaid, A., Khayati, Y., & Otmani, I. S. E. (2020) · Scientific African · doi:10.1016/j.sciaf.2020.e00685 · Cited by 144
Monoclonal antibody-based molecular imaging strategies and theranostic opportunities
Dammes, N., & Peer, D. (2020) · Theranostics · doi:10.7150/thno.37443 · Cited by 138
Bort, G., Lux, F., Dufort, S., Crémillieux, Y., Verry, C., & Tillement, O. (2020) · Theranostics · doi:10.7150/thno.37543 · Cited by 138
Tumor‐Targeting Glycol Chitosan Nanoparticles for Cancer Heterogeneity
Ryu, J. H., Yoon, H. Y., Sun, I., Kwon, I. C., & Kim, K. (2020) · Advanced Materials · doi:10.1002/adma.202002197 · Cited by 141
Martin, J. D., Panagi, M., Wang, C., Khan, T., Martin, M. R., Voutouri, C., Toh, K., Papageorgis, P., Mpekris, F., Polydorou, C., et al. (2019) · ACS Nano · doi:10.1021/acsnano.8b07865 · Cited by 138
The past, present, and future of breast cancer models for nanomedicine development
Boix-Montesinos, P., Soriano‐Teruel, P. M., Armiñán, A., Orzáez, M., & Vicent, M. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.018 · Cited by 146
Mesoporous Silica Nanoparticles: Properties and Strategies for Enhancing Clinical Effect
Frickenstein, A. N., Hagood, J. M., Britten, C. N., Abbott, B. S., McNally, M. W., Vopat, C. A., Patterson, E. G., MacCuaig, W. M., Jain, A., Walters, K. B., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040570 · Cited by 142
Integrating Nanotechnology into Cancer Care
Grodzinski, P. A., Kircher, M. F., Goldberg, M. S., & Gabizón, A. (2019) · ACS Nano · doi:10.1021/acsnano.9b04266 · Cited by 137
Nanomedicine and drug delivery systems in cancer and regenerative medicine
Garbayo, E., Pascual‐Gil, S., Rodríguez‐Nogales, C., Saludas, L., de Mendoza, A. E., & Blanco‐Prieto, M. J. (2020) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1637 · Cited by 140
Single- versus Dual-Targeted Nanoparticles with Folic Acid and Biotin for Anticancer Drug Delivery
Jurczyk, M., Jelonek, K., Musiał-Kulik, M., Beberok, A., Wrześniok, D., & Kasperczyk, J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030326 · Cited by 133
Ultrasound-responsive microbubbles and nanodroplets: A pathway to targeted drug delivery
Shakya, G., Cattaneo, M., Guerriero, G., Prasanna, A., Fiorini, S., & Supponen, O. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115178 · Cited by 137
Gold nanostructures: synthesis, properties, and neurological applications
Zare, I., Yaraki, M. T., Speranza, G., Najafabadi, A. H., Shourangiz-Haghighi, A., Nik, A. B., Manshian, B. B., Saraiva, C., Soenen, S. J., Kogan, M. J., et al. (2022) · Chemical Society Reviews · doi:10.1039/d1cs01111a · Cited by 133
Kopec̆ek, J., & Yang, J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.020 · Cited by 133
Yang, Z., Du, Y., Sun, Q., Peng, Y., Wang, R., Zhou, Y. J., Wang, Y., Zhang, C., & Qi, X. (2020) · ACS Nano · doi:10.1021/acsnano.0c02249 · Cited by 130
Solanki, R., Patel, K., & Patel, S. (2020) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2020.125501 · Cited by 129
Williford, J., Ishihara, J., Ishihara, A., Mansurov, A., Hosseinchi, P., Marchell, T. M., Potin, L., Swartz, M. A., & Hubbell, J. A. (2019) · Science Advances · doi:10.1126/sciadv.aay1357 · Cited by 125
Glutathione-responsive biodegradable polyurethane nanoparticles for lung cancer treatment
Iyer, R., Nguyen, T. P., Padanilam, D., Xu, C., Saha, D., Nguyen, K. T., & Hong, Y. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.02.021 · Cited by 127
Jiao, X., Sun, L., Zhang, W., Ren, J., Zhang, L., Cao, Y., Xu, Z., Kang, Y., & Xue, P. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120787 · Cited by 127
Charge-reversal nanocarriers: An emerging paradigm for smart cancer nanomedicine
Zhang, M., Chen, X., Li, C., & Shen, X. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.024 · Cited by 126
Redox-sensitive nanoscale drug delivery systems for cancer treatment
Mirhadi, E., Mashreghi, M., Maleki, M. F., Alavizadeh, S. H., Arabi, L., Badiee, A., & Jaafari, M. R. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119882 · Cited by 122
Liang, J., Li, X., Liu, H., Xia, J., Shi, X., & Shen, M. (2020) · Nano Today · doi:10.1016/j.nantod.2020.101022 · Cited by 121
Recent advances in nanoparticles mediated photothermal therapy induced tumor regression
Kumar, A. V. P., Dubey, S. K., Tiwari, S., Puri, A., Hejmady, S., Gorain, B., & Kesharwani, P. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120848 · Cited by 124
Metadata
- Authors
- Golombek, S. K., May, J.-N., Theek, B., Appold, L., Drude, N., Kiessling, F., & Lammers, T.
- Affiliations
- Universitätsklinikum Aachen (DE)
- Utrecht University (NL)
- Corresponding author
- Lammers, Twan
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 130
- Pages
- 17-38
- ISSN
- 0169-409X (ISSN-L)
- PMC
- PMC6130746
- OpenAlex
- W2884616676
- Cited by
- 1,262
- References
- 227
- Citations by year
- 2026: 118 · 2025: 115 · 2024: 121 · 2023: 124 · 2022: 200 · 2021: 261 · 2020: 221 · 2019: 93 · 2018: 7
- FWCI
- 9.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Advanced Drug Delivery Reviews (publishedVersion)
- PubMed (publishedVersion)
- University of Twente Research Information (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- University of Twente Research Information (submittedVersion, cc-by-nc-nd)
- Funders
- European Research Council (309495, 680882, 813086)
- German research Foundation (La2937/1-2, SFB/TRR57, SFB1066, GRK2375)
- European Union
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Physical Sciences › Engineering › Biomedical Engineering › Ultrasound and Hyperthermia Applications
- Keywords
- enhanced permeability and retention effect, tumor targeting, nanomedicine, tumor heterogeneity, precision oncology, tumor imaging, tumor accumulation
- MeSH terms
- Antineoplastic Agents, Humans, Neoplasms, Permeability, Drug Delivery Systems, Nanomedicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
